CMC Considerations for Biotechnology Product Development: A Regulatory Perspective

FDA discusses regulatory expectations for biotechnology products, regulatory challenges, and strategies for success.
Presenters:
Wendy Weinberg, PhD, Chief, Laboratory of Molecular Oncology
Kristen Nickens, PhD, Product Quality Team Lead
Office of Biotechnology Products (OBP), Office of Pharmaceutical Quality (OPQ), CDER
Learn more at: www.fda.gov/drugs/news-events...
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
Upcoming Training - www.fda.gov/cdersbia
SBIA Listserv - public.govdelivery.com/accoun...
SBIA 2021 Playlist - • 2021 CDER Small Busine...
SBIA LinkedIn: / cder-small-business-an...
SBIA Training Resources - www.fda.gov/cdersbialearn
Twitter - / fda_drug_info
Email - [e-mail]  
Phone - [phone] I [phone]